Guiding the design of HQ compounds: predictive ADME modeling and multi-parameter optimization

webinar

Tue, 08 Dec 2015, 17:00 CET (Berlin)

Dr. Matt Segall, CEO Optibrium, UK

Guiding the design of HQ compounds: predictive ADME modeling and multi-parameter optimization

Achieving target potency is not the only goal of lead optimization. To achieve efficacy and avoid safety issues, a high quality drug candidate must have an appropriate profile of absorption, distribution, metabolism and excretion (ADME) properties. Therefore, accurate predictions of these compound properties, while considering new ‘virtual’ compounds, can guide the design process toward compounds that achieve a balance of potency with these other requirements, improving efficiency and reducing the risk of late-stage failures that can cost R&D departments millions of Euros.

In this webinar Dr. Segall, CEO of Opbitrium, will describe the development and validation of quantitative structure-activity relationship (QSAR) models of key ADME properties, such as lipophilicity, solubility, absorption, hERG inhibition and blood-brain barrier penetration. He will consider the confidence in the predictions of such models and how this relates to their domains of applicability.

He will also explore how predictive models can be used as part of a true multi-parameter optimisation environment to select high quality compounds, with an optimal balance of properties, while explicitly considering uncertainties to avoid missed opportunities. Furthermore, the Glowing MoleculeTM visualization highlights regions of a compound with a strong influence on a predicted property, to guide the design of compounds with improved properties. This will be illustrated with Optibrium’s StarDropTM software.

Finally, we will discuss how the approaches of structure-based design and multi-parameter optimisation can be brought together, the focus of the collaboration between Optibrium and BioSolveIT. Dr. Segall will demonstrate how StarDrop’s ADME QSAR models have been integrated within SeeSAR to monitor these properties while considering design strategies in 3D. He will also motivate how SeeSAR will be integrated with StarDrop, to seamlessly link 2D and 3D SAR and identify new strategies for optimisation.

Current news

category
Events
Announcing BioSolveIT's DrugSpace Symposium 2025: Bridging Science
June 26, 2025 09:43 CEST
We are pleased to announce the fourth edition of the BioSolveIT DrugSpace Symposium, taking place on September 24–25, 2025. This year’s theme, “Bridging Science,” highlights the growing importance of interdisciplinary collaboration in driving innovation across the drug discovery landscape. As the field evolves, it becomes increasingly clear that real progress...
Read on
Psst... Are You Following Us Yet? Follow the Science (and a Bit More)
June 25, 2025 08:44 CEST
There’s a lot going on behind the scenes—ideas taking shape, tools evolving, science in motion. And while the website tells you what our software does, our social media gives you a look at how it lives. We’re active on LinkedIn, BlueSky, and YouTube, sharing everything from scientific snapshots to educational...
Read on
AMBrosia Just Got Bigger: 126 Billion Compound Update Now Available
June 11, 2025 13:21 CEST
We are thrilled to announce a major update to the AMBrosia Chemical Space in collaboration with Ambinter! The state-of-the-art source for diverse drug-like scaffolds now boasts an incredible 126 billion of synthetically accessible compounds for drug discovery projects. What does the update feature? Expanded to an astounding 125,924,571,692 compounds (1.26...
Read on